Latest Pharma Insights
Multiple Chinese Biotechs Close Back-to-Back Funding Rounds
Since late April, Chinese ventures Best-Link, Starna and Vivacta have closed moderate new financing rounds backed by venture capital and private equity firms within just six months of their last fundraisings.
Scrip - May 19, 2026
Since late April, Chinese ventures Best-Link, Starna and Vivacta have closed moderate new financing rounds backed by venture capital and private equity firms within just six months of their last fundraisings.
Scrip - May 19, 2026
US Consumer Health Industry People Moves: Haleon, CeraVe, Nutrabolt, CHPA, More
Haleon’s US marketing chief has Google experience; CHPA Foundation chief adds public affairs post; Nutrabolt adds CPG industry veteran; CeraVe launches campaign with NBA great Anthony; private equity partner has consumer health background; and bio-protein developer Every names first CRO.
HBW Insight - May 19, 2026
Haleon’s US marketing chief has Google experience; CHPA Foundation chief adds public affairs post; Nutrabolt adds CPG industry veteran; CeraVe launches campaign with NBA great Anthony; private equity partner has consumer health background; and bio-protein developer Every names first CRO.
HBW Insight - May 19, 2026
Flagship Eyes Long-Term Partnerships, Biopharma Ecosystem Growth In Korea
Flagship Pioneering's APAC head and special advisor share strategies to tap into rising Korean biopharma innovation as the US group seeks new partnerships and to apply its company creation model to the local ecosystem.
Scrip - May 19, 2026
Flagship Pioneering's APAC head and special advisor share strategies to tap into rising Korean biopharma innovation as the US group seeks new partnerships and to apply its company creation model to the local ecosystem.
Scrip - May 19, 2026
US FDA Acting Foods Program Chief Is Familiar To Dietary Supplement Industry
Agency updates Donal Prater’s biography on its website to indicate he is leading Human Foods Program as acting deputy commissioner for food, the post held by Kyle Diamantas until he was named acting commissioner following May 12 resignation of Martin Makary.
HBW Insight - May 19, 2026
Agency updates Donal Prater’s biography on its website to indicate he is leading Human Foods Program as acting deputy commissioner for food, the post held by Kyle Diamantas until he was named acting commissioner following May 12 resignation of Martin Makary.
HBW Insight - May 19, 2026
US Personal Care Exports Could Fall $1.9Bn Without USMCA
A PCPC-backed analysis warns that ending or weakening USMCA trade protections could reduce US personal care exports by $1.9bn and disrupt the North American beauty industry’s integrated supply chains.
HBW Insight - May 19, 2026
A PCPC-backed analysis warns that ending or weakening USMCA trade protections could reduce US personal care exports by $1.9bn and disrupt the North American beauty industry’s integrated supply chains.
HBW Insight - May 19, 2026
Multiple Chinese Biotechs Close Back-to-Back Funding Rounds
Since late April, Chinese ventures Best-Link, Starna and Vivacta have closed moderate new financing rounds backed by venture capital and private equity firms within just six months of their last fundraisings.
Scrip - May 19, 2026
Since late April, Chinese ventures Best-Link, Starna and Vivacta have closed moderate new financing rounds backed by venture capital and private equity firms within just six months of their last fundraisings.
Scrip - May 19, 2026
Flagship Eyes Long-Term Partnerships, Biopharma Ecosystem Growth In Korea
Flagship Pioneering's APAC head and special advisor share strategies to tap into rising Korean biopharma innovation as the US group seeks new partnerships and to apply its company creation model to the local ecosystem.
Scrip - May 19, 2026
Flagship Pioneering's APAC head and special advisor share strategies to tap into rising Korean biopharma innovation as the US group seeks new partnerships and to apply its company creation model to the local ecosystem.
Scrip - May 19, 2026
Perspective: What Architecture Tells Us About Safely Navigating Generative AI Risks in Medtech
Generative AI in medtech carries risks unlike other sectors. Risk accumulates across the full pipeline — foundation model, RAG layer, and agentic tools — and splits into embedded (bias, hallucinations) and enacted (automation bias) categories. Compliant deployment requires careful planning.
Medtech Insight - May 18, 2026
Generative AI in medtech carries risks unlike other sectors. Risk accumulates across the full pipeline — foundation model, RAG layer, and agentic tools — and splits into embedded (bias, hallucinations) and enacted (automation bias) categories. Compliant deployment requires careful planning.
Medtech Insight - May 18, 2026
India’s Medtech Sector Eyes $80bn Opportunity As Domestic Manufacturing Share Doubles In 3 Years
India's medical device sector has hit a genuine turning point – domestic manufacturing share has doubled, capital is flooding in, and a clutch of homegrown innovations are reaching global markets. A new report sets out exactly what is at stake and what could still go wrong.
Medtech Insight - May 18, 2026
India's medical device sector has hit a genuine turning point – domestic manufacturing share has doubled, capital is flooding in, and a clutch of homegrown innovations are reaching global markets. A new report sets out exactly what is at stake and what could still go wrong.
Medtech Insight - May 18, 2026
Boston Scientific Bets $1.5bn On MiRus, Secures Option To Acquire TAVR System
The medtech giant re-enters the TAVR arena, after two major platform failures, with a 34% stake in MiRus and an exclusive option to acquire its nickel-free SIEGEL valve.
Medtech Insight - May 18, 2026
The medtech giant re-enters the TAVR arena, after two major platform failures, with a 34% stake in MiRus and an exclusive option to acquire its nickel-free SIEGEL valve.
Medtech Insight - May 18, 2026
BIA’s 2035 Vision For UK Health Data Goes Beyond Subscription Models
With over 200 large-scale patient datasets already competing globally, the BIA argues a subscription-fee mindset would lock out UK SMEs and hand the upside to better-funded foreign rivals.
Medtech Insight - May 18, 2026
With over 200 large-scale patient datasets already competing globally, the BIA argues a subscription-fee mindset would lock out UK SMEs and hand the upside to better-funded foreign rivals.
Medtech Insight - May 18, 2026
US Consumer Health Industry People Moves: Haleon, CeraVe, Nutrabolt, CHPA, More
Haleon’s US marketing chief has Google experience; CHPA Foundation chief adds public affairs post; Nutrabolt adds CPG industry veteran; CeraVe launches campaign with NBA great Anthony; private equity partner has consumer health background; and bio-protein developer Every names first CRO.
HBW Insight - May 19, 2026
Haleon’s US marketing chief has Google experience; CHPA Foundation chief adds public affairs post; Nutrabolt adds CPG industry veteran; CeraVe launches campaign with NBA great Anthony; private equity partner has consumer health background; and bio-protein developer Every names first CRO.
HBW Insight - May 19, 2026
US FDA Acting Foods Program Chief Is Familiar To Dietary Supplement Industry
Agency updates Donal Prater’s biography on its website to indicate he is leading Human Foods Program as acting deputy commissioner for food, the post held by Kyle Diamantas until he was named acting commissioner following May 12 resignation of Martin Makary.
HBW Insight - May 19, 2026
Agency updates Donal Prater’s biography on its website to indicate he is leading Human Foods Program as acting deputy commissioner for food, the post held by Kyle Diamantas until he was named acting commissioner following May 12 resignation of Martin Makary.
HBW Insight - May 19, 2026
US Personal Care Exports Could Fall $1.9Bn Without USMCA
A PCPC-backed analysis warns that ending or weakening USMCA trade protections could reduce US personal care exports by $1.9bn and disrupt the North American beauty industry’s integrated supply chains.
HBW Insight - May 19, 2026
A PCPC-backed analysis warns that ending or weakening USMCA trade protections could reduce US personal care exports by $1.9bn and disrupt the North American beauty industry’s integrated supply chains.
HBW Insight - May 19, 2026
Amgen’s At-Risk Eylea Biosimilar Paved The Path For Biocon’s US Launch, Says CEO
Profitable growth over market share grabs, a capacity-doubled Malaysia facility and a succession plan in the making: Biocon is quietly reshaping itself for the long haul.
Generics Bulletin - May 18, 2026
Profitable growth over market share grabs, a capacity-doubled Malaysia facility and a succession plan in the making: Biocon is quietly reshaping itself for the long haul.
Generics Bulletin - May 18, 2026
Dr Reddy’s Follows Apotex With Second Semaglutide In Canada
A second Ozempic generic has hit the Canadian market, with Dr Reddy’s following hot on the heels of Apotex with its own semaglutide offering.
Generics Bulletin - May 18, 2026
A second Ozempic generic has hit the Canadian market, with Dr Reddy’s following hot on the heels of Apotex with its own semaglutide offering.
Generics Bulletin - May 18, 2026
Henlius Takes Cetuximab Biosimilar Development Outside Of China
Henlius has secured US FDA clearance for an IND for its proposed biosimilar to Erbitux (cetuximab), advancing a contender in a field where scientific complexity has kept US and European markets without an approved biosimilar.
Generics Bulletin - May 18, 2026
Henlius has secured US FDA clearance for an IND for its proposed biosimilar to Erbitux (cetuximab), advancing a contender in a field where scientific complexity has kept US and European markets without an approved biosimilar.
Generics Bulletin - May 18, 2026
EU Biotech Act’s SPC Extension Sparks Access And Cost Concerns
A proposed 12-month SPC extension for qualifying biotech medicines under the European Biotech Act has drawn sharp criticism from biosimilars firms, payers and patients, who warn it risks delaying competition by a year while doing little to drive European manufacturing investment.
Generics Bulletin - May 18, 2026
A proposed 12-month SPC extension for qualifying biotech medicines under the European Biotech Act has drawn sharp criticism from biosimilars firms, payers and patients, who warn it risks delaying competition by a year while doing little to drive European manufacturing investment.
Generics Bulletin - May 18, 2026
Bio-Thera And Accord Take Lead With First US Golimumab Nod
Bio-Thera Solutions and Accord Biopharma have together broken new ground in the US after receiving the first FDA approvals for golimumab biosimilars in the form of their partnered Immgolis and Immgolis Intri rivals to Simponi and Simponi Aria.
Generics Bulletin - May 18, 2026
Bio-Thera Solutions and Accord Biopharma have together broken new ground in the US after receiving the first FDA approvals for golimumab biosimilars in the form of their partnered Immgolis and Immgolis Intri rivals to Simponi and Simponi Aria.
Generics Bulletin - May 18, 2026
Deals In Depth: April 2026
Six $1bn+ alliances were penned in April, and three exceeded $2bn. In the top alliance by deal value, Profluent entered a potential $2.25bn multi-program collaboration with Eli Lilly to develop and commercialize custom site-specific recombinases to address diseases with severe unmet needs.
In Vivo - May 18, 2026
Six $1bn+ alliances were penned in April, and three exceeded $2bn. In the top alliance by deal value, Profluent entered a potential $2.25bn multi-program collaboration with Eli Lilly to develop and commercialize custom site-specific recombinases to address diseases with severe unmet needs.
In Vivo - May 18, 2026
The Alkermes Handover: Ambition, Jazz Settlement And Phase III Still To Come
Outgoing CEO Richard Pops built Alkermes. Now he is handing it over at precisely the moment his biggest wager on sleep medicine is entering its most consequential phase.
In Vivo - May 18, 2026
Outgoing CEO Richard Pops built Alkermes. Now he is handing it over at precisely the moment his biggest wager on sleep medicine is entering its most consequential phase.
In Vivo - May 18, 2026